Tianjin Suntech Pharmaceutical Technology Co.
Latest round
- Series C
Last raised
- May 2022
Total raised
- Undisclosed
Investors
- 3
About Tianjin Suntech Pharmaceutical Technology Co.
, Ltd. has research and development centers in Australia and China. The company mainly engages in the development of new drugs for anti-cancer stem cells and autoimmune diseases and has obtained 9 phase 1-2 clinical trial approvals in China, the United States and Australia, etc. The company's product ACT001 has been granted orphan drug status in the United States and the European Union, and is one of the top 10 products independently developed in China to obtain orphan drug status in the United States. The company was ranked No. 100 in the 2020 China Chemical Research and Development Strength Ranking, the founders of the company Prof. Peng Wang is a Changjiang Scholar and Claude S. Hudson Award recipient, and Yue Chen is a National Outstanding Youth Fund recipient. The company develops products with special focus on active ingredients in Chinese medicine, using modern medicinal chemistry strategies for structural optimization, resulting in drug candidates with new structures and mechanisms, which should mainly fight against cancer stem cells and autoimmune diseases, with a focus on new drugs that enter the cranium. The company currently has two unique technology platforms, namely "Open/Modulated Blood-Brain Barrier Platform" and "Cancer Stem Cell Targeted Drug Development Platform". The company is currently known to manufacture ACT001, mainly for children with DIPG; meanwhile, the results of the company's clinical phase 1b/2a trial of combined radiotherapy for the treatment of brain metastases from cancer have been included in ASCO (Abstract#366152)., phase II in Australia for pulmonary fibrosis, and phase II in China for brain metastases from cancer.
Who invested in Tianjin Suntech Pharmaceutical Technology Co.
3 investors across 1 round
See all investors in Tianjin Suntech Pharmaceutical Technology Co.
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series C
May 1, 2022
Amount
Undisclosed
Investors
Questions about Tianjin Suntech Pharmaceutical Technology Co.
Who invested in Tianjin Suntech Pharmaceutical Technology Co.?
Tianjin Suntech Pharmaceutical Technology Co. has 3 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Tianjin Suntech Pharmaceutical Technology Co. raised?
Tianjin Suntech Pharmaceutical Technology Co. has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Tianjin Suntech Pharmaceutical Technology Co. last raise money?
Tianjin Suntech Pharmaceutical Technology Co.'s most recent round on record is a Series C, in May 2022.
What does Tianjin Suntech Pharmaceutical Technology Co. do?
Tianjin Suntech Pharmaceutical Technology Co. is a pharmaceuticals company.
Where is Tianjin Suntech Pharmaceutical Technology Co. headquartered?
Tianjin Suntech Pharmaceutical Technology Co. is headquartered in Tianjin, China.
Which VCs invest in companies like Tianjin Suntech Pharmaceutical Technology Co.?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back pharmaceuticals companies at Tianjin Suntech Pharmaceutical Technology Co.'s stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series C
Raising like Tianjin Suntech Pharmaceutical Technology Co.? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.